KOSDAQIT & Software288980

Moadata

₩521 0.00%2026-11-18 close
Market Cap
₩3.9B
Turnover
₩0
Volume
0 shares
Shares out.
7.5M
PER
—
PBR
—
EPS
-₩5,145
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Moadata: Losses and Balance-Sheet Strain Take Center Stage

Moadata's revenue fell and its losses widened in 2025, and it has recorded losses for five consecutive quarters through the third quarter of 2026, leaving funding and balance-sheet strength as the central issues to monitor.

  1. 1

    Revenue for 2025 was KRW 23.2 billion, down 32.6% year on year, and the operating loss widened to KRW 5.93 billion.

  2. 2

    Third-quarter 2026 revenue was KRW 427 million, down 93.5% from the prior quarter, and the net loss attributable to controlling shareholders was KRW 14.4 billion.

  3. 3

    Net losses attributable to controlling shareholders over the last four quarters totaled KRW 38.6 billion, more than the KRW 18 billion of controlling-shareholder equity at the end of 2025.

  4. 4

    The debt ratio rose from 50.5% in 2022 to 303.8% in 2025, and operating cash flow has been negative since 2024.

  5. 5

    In November 2026 the company was designated an unfaithful-disclosure entity and carried out a share consolidation that raised the par value from KRW 500 to KRW 2,500, and it agreed to repurchase KRW 1.75 billion of its 11th convertible bonds before maturity.

02

Business structure

Moadata is a software company whose core business is AI-based anomaly detection and predictive analytics solutions. Founded in 2014, it listed on KOSDAQ in March 2022. Its flagship product is PetaOn Forecaster, a deep-learning AIOps solution that the company says it first commercialized in Korea in 2015.

The business is divided into two segments, AI anomaly detection and digital healthcare. The AI anomaly detection segment covers products that identify server and IT infrastructure failures in advance, and its revenue fell in 2025 as orders declined.

The digital healthcare segment expanded through the acquisition of a healthcare specialist after the listing, and its revenue rose in 2025 on data business and R&D activity. However, neither segment offset the broader decline, so consolidated results worsened in 2025.

Customers are centered on public, financial and corporate clients, and the company's profile cites more than 300 customers. Among peers in the same sector, the company is small relative to large IT services groups such as Samsung SDS, LG CNS and Hyundai Autoever.

According to a News Worker report, 2024 cost of sales was KRW 21.1 billion and SG&A expenses were KRW 14.5 billion, so most of the sales growth was absorbed by higher costs.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩7B-₩1.6B−22.8%
2025Q4₩6.4B-₩2.3B−35.9%
2026Q1₩4.4B-₩2.3B−51.5%
2026Q2₩6.5B-₩1.4B−22.0%
2026Q3₩400M-₩4.4B−1026.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩21.7B₩1.1B₩1.8B5.0%4.8%50.5%
2023₩24.5B-₩400M₩200M−1.5%0.6%82.2%
2024₩34.4B-₩1.3B-₩3.4B−3.9%−9.1%136.4%
2025₩23.2B-₩5.9B-₩19.7B−25.6%−109.4%303.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual results grew in scale through 2024 before turning down in 2025. Revenue rose from KRW 21.7 billion in 2022 to KRW 24.5 billion in 2023 (up 13.0% year on year) and peaked at KRW 34.4 billion in 2024 (up 40.1%), the largest year in the 2022 to 2025 span. Revenue then fell 32.6% to KRW 23.2 billion in 2025.

Profitability moved in the opposite direction. Operating profit of KRW 1.08 billion in 2022 turned into an operating loss of KRW 358 million in 2023, followed by an operating loss of KRW 1.33 billion in 2024 and KRW 5.93 billion in 2025. The operating margin fell from 5.0% in 2022 to -25.6% in 2025.

Net income attributable to controlling shareholders dropped from KRW 1.79 billion in 2022 to KRW 244 million in 2023 (down 86.4%), then turned into a net loss of KRW 3.38 billion in 2024 and KRW 19.7 billion in 2025, the largest loss in the 2022 to 2025 span.

Net income including non-controlling interests is a different figure, with net losses of KRW 583 million in 2023, KRW 4.09 billion in 2024 and KRW 19.7 billion in 2025.

The company attributed the 2025 operating loss to lower revenue, a larger bad-debt provision after a counterparty filed for bankruptcy, and higher depreciation from newly acquired R&D equipment.

It said a rise in equity-method losses from associates and lower gains on derivatives linked to CB and BW deepened the net loss. Operating cash flow was positive at KRW 1.68 billion in 2022 and KRW 792 million in 2023, then turned negative at -KRW 1.28 billion in 2024 and -KRW 1.84 billion in 2025.

The debt ratio climbed from 50.5% in 2022 to 82.2% in 2023, 136.4% in 2024 and 303.8% in 2025. At the end of 2025 total liabilities were KRW 58.8 billion against total equity of KRW 19.4 billion, of which KRW 18 billion belonged to controlling shareholders. The quarterly picture is sharper.

Revenue went from KRW 7.01 billion in the third quarter of 2025 to KRW 6.44 billion in the fourth quarter, KRW 4.39 billion in the first quarter of 2026 and KRW 6.53 billion in the second quarter, before falling to KRW 427 million in the third quarter of 2026, down 93.5% from the prior quarter and 93.9% from a year earlier.

Operating losses ran at KRW 1.6 billion, KRW 2.31 billion, KRW 2.26 billion, KRW 1.44 billion and KRW 4.38 billion across the same five quarters.

Net losses attributable to controlling shareholders widened from KRW 2.5 billion in the third quarter of 2025 to KRW 11.5 billion in the fourth quarter, narrowed to KRW 3.46 billion in the first quarter of 2026, then widened again to KRW 9.31 billion and KRW 14.4 billion. The four-quarter total is KRW 38.6 billion.

05

Industry analysis

Moadata operates in the AIOps segment, which automates IT infrastructure operations. According to a FnGuide company summary, the AIOps market is forecast to grow from USD 11.7 billion in 2023 to USD 32.4 billion in 2028, a compound annual growth rate of 22.7%.

This is a market research estimate, and market growth does not translate directly into the company's revenue. The 2025 decline in orders for the AI anomaly detection segment shows that revenue depends heavily on the IT spending timing of individual clients.

Competitively, large IT services groups can bundle platforms and infrastructure, which makes it harder for single-product vendors to compete on price and reference wins. Moadata's strengths are its commercial track record since 2015 and its public and financial client base.

Its scale and capital base, however, trail those of the larger sector players. The digital healthcare segment sits where demand for data analytics is widening into health care, but the company's market size and share for that segment are not yet quantified.

The most important industry question is whether the sharp drop in third-quarter 2026 revenue reflects a temporary gap in orders or client losses and contract reductions. The 2026 annual report's segment disclosure should help answer it.

06

Outlook

The nearest confirmed event is the payment for the repurchase of 11th-series convertible bonds. On October 26, 2026, the board approved buying bonds with a face value of KRW 1.75 billion off-market, and the repurchase amount of KRW 1.87 billion has a payment date of November 30, 2026.

After the repurchase the outstanding face value will be zero, and the funding source is recorded as own funds and borrowings. On November 5, 2026, the company was designated an unfaithful-disclosure entity because of a change of more than 20% in the share consolidation ratio, with 4.0 penalty points.

On November 11, 2026, a share consolidation raising the par value from KRW 500 to KRW 2,500 took effect.

In that process the holding ratio of CEO Han Sang-jin and related parties fell to 2.69% as of November 18, 2026, and the filing attributes the change to the consolidation and to market sales linked to forced liquidation of pledged shares. The next earnings checkpoint is the 2026 fiscal year close.

The 2025 fiscal year results were disclosed alongside a board resolution on February 27, 2026. For a December fiscal year-end company, the annual report filing deadline is 90 days after year-end, which is March 31, 2027.

On the business side, the key checkpoints are whether orders in the AI anomaly detection segment recover and whether data business revenue in digital healthcare continues after the third quarter of 2026.

07

Valuation

PER
—
PBR
—
ROE
-294.2%
EPS
-₩5,145
BPS
—
Dividend per share
₩0

Because the company has posted net losses over the last four quarters, a multiple based on earnings cannot be calculated. Market capitalization sits below the KRW 18 billion of controlling-shareholder equity at the end of 2025, so the stock trades below its book value on that basis.

Controlling-shareholder equity fell sharply between the end of 2024 and the end of 2025 as losses eroded the balance sheet. A comparison against book equity changes meaning each quarter the losses accumulate, so it should be read alongside the quarterly series.

With operating cash flow negative, capacity to pay dividends from cash generation is limited. A debt ratio of 303.8% means liabilities are more than three times equity, which indicates high financial leverage.

The 2026 share consolidation reduced the number of shares outstanding, so per-share comparisons with earlier periods require adjusting for the change in units. Measured against profits in the earlier profitable years, the current valuation position depends on whether earnings recover.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Early commercialization and a reference base

Moadata says it commercialized an AIOps solution in Korea in 2015 and has built references across public and financial clients with a base of more than 300 customers. If the projected 22.7% annual market growth materializes, the existing client base could serve as a starting point for demand recovery. The technology head start and customer base remain business assets even after revenue declined in 2025.

Revenue growth in the digital healthcare segment

In 2025, when orders for the AI anomaly detection segment declined, the digital healthcare segment still grew revenue on data business and R&D. Because the two segments rely on different sources of demand, the structure can partly absorb an order gap in one of them. The segment sits where demand for healthcare data is widening, which leaves room for expansion.

Possible debt reduction from bond repurchase

If the repurchase of KRW 1.75 billion of 11th-series convertible bonds, approved by the board in October 2026, is completed, the outstanding face value will be zero. A lower bond balance would reduce future dilution from conversion and part of the debt service burden.

The company says it will fund the repurchase with own funds and borrowings. Whether the debt structure improves will show up in the 2026 fiscal year financial statements.

09

Bear factors

Continued losses and a sharp revenue drop

Third-quarter 2026 revenue was KRW 427 million, down 93.5% from the prior quarter, while the operating loss rose to KRW 4.38 billion and the net loss attributable to controlling shareholders widened to KRW 14.4 billion.

Losses have continued for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026. Cumulative net losses over the last four quarters total KRW 38.6 billion. Quarterly revenue has swung widely, which makes it hard to describe the earnings base as stable.

High leverage and negative operating cash flow

The debt ratio reached 303.8% in 2025, more than triple the 50.5% of 2022. Operating cash flow stayed negative at -KRW 1.28 billion in 2024 and -KRW 1.84 billion in 2025. A Daily Yonhap report put the cumulative issuance of convertible bonds over the most recent five years at KRW 42.9 billion.

If the company continues to rely on external funding, changes in interest rates and repayment terms could weigh on it.

Governance and disclosure credibility

On November 5, 2026, the company was designated an unfaithful-disclosure entity over a change of more than 20% in its share consolidation ratio.

In the same month a share consolidation raised the par value from KRW 500 to KRW 2,500, and the CEO's side reduced its holding to 2.69% as of November 18, 2026, amid forced sales of pledged shares.

According to a News Worker report, the company received CEO guarantees totaling KRW 6.245 billion in borrowings as of the end of 2024. Changes in the controlling holders' stakes and the guarantee structure are linked to the company's funding conditions.

10

Risk factors

Liquidity and funding risk

The repurchase payment of KRW 1.87 billion for the 11th-series convertible bonds is due on November 30, 2026, and will be funded with own funds and borrowings. With operating cash flow negative, the company depends on external financing, so cash capacity after the payment matters.

Reports indicate cumulative bond issuance exceeds year-end cash, so any further financing could come on less favorable terms.

Listing and disclosure-rule risk

The designation as an unfaithful-disclosure entity on November 5, 2026 centered on a change to a disclosed share consolidation ratio. The consolidation changed both the number of shares and the par value, which affects trading units and share price comparisons. Further steps under exchange disclosure rules and the accuracy of corrective filings could come under review.

Business and client concentration risk

The AI anomaly detection segment can see orders fall with the timing of clients' IT investment, and revenue did decline in 2025. The larger bad-debt provision after a counterparty filed for bankruptcy shows that the collection risk on a single counterparty can flow directly into results. Growth in the digital healthcare segment is not yet confirmed to offset this risk.

11

What to watch next

  1. November 30, 2026

    Payment of the KRW 1.87 billion repurchase amount for the 11th-series convertible bonds and the mix of funding sources. The split between own funds and borrowings will show how much cash capacity remains and whether more financing is needed.

  2. End of December 2026 (2026 fiscal year close)

    Whether fourth-quarter 2026 revenue recovers from the KRW 427 million recorded in the third quarter. The size of the fourth-quarter operating loss and net loss attributable to controlling shareholders, compared with the KRW 2.31 billion and KRW 11.5 billion recorded in the fourth quarter of 2025, is the next checkpoint.

  3. By March 31, 2027 (2026 annual report filing deadline)

    Full-year 2026 revenue, operating loss and debt ratio in the annual report, along with segment explanations. The segment revenue trends for AI anomaly detection and digital healthcare, and the notes on bad-debt provisions and derivative valuation, are the main items to check.

  4. Around May 15, 2027 (Q1 2027 quarterly report filing deadline)

    Whether first-quarter 2027 revenue continues the trend since the third quarter of 2026 and whether the loss narrows. If losses persist, changes in the equity and debt structure will be the next checkpoint.

12

Overall view

Moadata's recent results show revenue growth followed by a simultaneous deterioration in profitability and cash generation. The operating margin fell from 5.0% in 2022 to -25.6% in 2025, and revenue of KRW 23.2 billion in 2025 was down 32.6% year on year.

In the third quarter of 2026 revenue fell to KRW 427 million and the net loss attributable to controlling shareholders widened to KRW 14.4 billion, bringing the four-quarter total to KRW 38.6 billion.

On the financial side, the debt ratio rose to 303.8% and operating cash flow has been negative since 2024, while convertible bond issuance and CEO guarantees have been reported as key funding tools.

Strengths include early commercialization of AIOps technology, the client base and room for growth in healthcare, while weaknesses include revenue volatility, accumulated losses and a heavy debt burden.

Market forecasts point to growth in AIOps demand, but the company's revenue is currently moving in a different direction. The next checkpoints are the use of funds for the November 30, 2026 bond repurchase, the 2026 fiscal year close, and whether revenue recovers in the first quarter of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.wisereport.co.kr
  2. thevc.kr
  3. comp.fnguide.com
  4. digitaltoday.co.kr
  5. digitaltoday.co.kr
  6. news.nate.com
  7. innoforest.co.kr
  8. newsworker.co.kr
  9. dailyan.com
  10. digitaltoday.co.kr
  11. investing.com
  12. digitaltoday.co.kr
  13. digitaltoday.co.kr
  14. valueline.co.kr
  15. digitaltoday.co.kr
  16. digitaltoday.co.kr

Report written 2026-11-19 · Data as of 2026-11-18

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis